Covalon to Present FDA Cleared IV ClearT Antimicrobial Silicone Adhesive Dressing at FIME: the Largest International Medical Trade Fair and Congress in the United States
MISSISSAUGA, ON, Aug. 8, 2012 /PRNewswire/ - Covalon Technologies Ltd., an advanced medical technologies company, today announced that it is presenting its latest breakthrough antimicrobial products, including the recently United States FDA cleared IV ClearT at the 2012 FIME International Medical Expo ("FIME") from August 8 to 10 in Miami Beach, Florida.
As a seminar guest speaker, Dr. Val DiTizio, Covalon's Chief Scientific Officer will be discussing why IV Clear is being evaluated by medical institutions that have adopted programs focused on reducing the instances of catheter related bloodstream infections. Clinicians have identified patients who have weak immune systems, sensitive or compromised skin, or who have long-term catheters as groups who can benefit the most from IV Clear. Dr. DiTizio's seminar entitled "A Novel Antimicrobial Clear IV Dressing with Chlorhexidine and Silver" will be presented at 10:00am in room D238 during the FIME Medical Educational Conference on Thursday August 9th at the Miami Beach Convention Center.
Covalon will also be showcasing its latest wound care products such as ColActive@ Plus Ag, which is cleared for use in the management of diabetic ulcers and other chronic wounds and SurgiClearT, its unique antimicrobial transparent silicone adhesive surgical dressing to the thousands of international and domestic distributors, group purchasing organizations, hospitals and medical products dealers attending FIME who are looking for advanced products to license and distribute.
"IV Clear is truly a new innovation in the fight against Catheter Related Blood Stream Infections ("CRBSI") and we fully expect IV Clear to be a strong competitor in the United States and International markets," stated Brian Pedlar, Covalon's Chief Executive Officer. "We are looking forward to establishing new distribution relationships at FIME with distributors and hospital buying groups that are interested in sourcing and licensing IV Clear and other Covalon products." FIME International Medical Expo, is the largest international medical trade fair and congress in the United States for conventional medical distributor networks, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities, and home and durable medical equipment providers seeking the latest medical products from all over the world.
To learn more about Covalon's products and services, please visit Covalon at booth #365 in the Miami Beach Convention Center in Miami Beach, Florida from August 8 to 10, 2012 or contact Covalon directly: Brian Pedlar CEO, Covalon Technologies Ltd.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.